The road not taken: Antigen-specific therapy and neuroinflammatory disease

JAMA Neurology

Volumn 70, Issue 9, 2013, Pages 1100-1101

  Steinman, Lawrence ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AQUAPORIN 4; C PEPTIDE; CD20 ANTIBODY; CHOLINERGIC RECEPTOR; DNA VACCINE; FINGOLIMOD; INTERLEUKIN 10; MYELIN BASIC PROTEIN; MYELIN BASIC PROTEIN 85-99; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN OLIGODENDROGLIAL GLYCOPROTEIN 35-55; PLACEBO; PROINSULIN; PROTEOLIPID PROTEIN; PROTEOLIPID PROTEIN PEPTIDE 139-151; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; CYTOKINE PRODUCTION; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; DRUG TARGETING; EDITORIAL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; LANGERHANS CELL; LYMPHOCYTOPENIA; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYELOOPTIC NEUROPATHY; NERVOUS SYSTEM INFLAMMATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

EID: 84883817922     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.3553     Document Type: Editorial

References (15)

1. Frost R. The Road Not Taken. In: Mountain Interval. New York, NY: Henry Holt and Co; 1916:9.
2. Hauser SL, Waubant E, Arnold DL, et al HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676-688. (Pubitemid 351240747)
3. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011;378(9805):1779-1787.
4. Coles AJ, Compston DA, Selmaj KW, et al; CAMMS223 Trial Investigators. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786-1801.
5. Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010;9(11):883-897.
6. Walczak A, Siger M, Ciach A, SzczepanikM, Selmaj K. Transdermal application of myelin peptides in multiple sclerosis treatment [published online July 1, 2013]. JAMA Neurol. doi:10.1001/jamaneurol.2013.3022.
7. Juryńczyk M,Walczak A, Jurewicz A, Jesionek-Kupnicka D, Szczepanik M, Selmaj K. Immune regulation of multiple sclerosis by transdermally appliedmyelin peptides. Ann Neurol. 2010;68(5):593-601.
8. Coles AJ, Twyman CL, Arnold DL, et al; CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829-1839.
9. Lutterotti A, SospedraM, Martin R. Antigen-specific therapies in MS: current concepts and novel approaches. J Neurol Sci. 2008;274(1-2):18-22.
10. Garren H, Robinson WH, Krasulová E, et al; BHT-3009 Study Group. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann Neurol. 2008;63(5):611-620.
11. Sabatos-Peyton CA, Verhagen J, Wraith DC. Antigen-specific immunotherapy of autoimmune and allergic diseases. Curr Opin Immunol. 2010;22(5):609-615.
12. Ho PP, Kanter JL, Johnson AM, et al. Identification of naturally occurring fatty acids of themyelin sheath that resolve neuroinflammation. Sci Transl Med. 2012;4(137):37ra73.
13. Tradtrantip L, Zhang H, Saadoun S, et al. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol. 2012;71(3):314-322.
14. Roep BO, Solvason N, Gottlieb PA, et al. Plasmid encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8 T cells in type 1 diabetes. Sci Transl Med. In press.
15. Steinman L, Axtell RC, Barbieri D, et al. Piet Mondrian's trees and the evolution in understanding multiple sclerosis, Charcot Prize Lecture 2011. Mult Scler. 2013;19(1):5-14.